SCHEMBL31400488

SCHEMBL31400488

Cc1ccc(C(=O)NCc2cc3nc(N4CCC[C@H](c5cccnc5)C4)ccc3cn2)cc1S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.38
▸ KCNJ1 P48048 1/20 0.38
▸ MAP4K4 O95819 2/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ LMNA P02545 2/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ GAA P10253 1/20 0.35
▸ CCNE1 P24864 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ POLB P06746 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31400464 1.00 PDE10A (0.38) PDE10AKCNJ1MAP4K4SMN1; SMN2ALDH1A1
SCHEMBL31400594 1.00 PDE10A (0.38) PDE10AKCNJ1MAP4K4SMN1; SMN2ALDH1A1
SCHEMBL31400884 0.96 PDE10A (0.42) PDE10AKCNJ1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL31400908 0.96 PDE10A (0.42) PDE10AKCNJ1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL31400522 0.96 PDE10A (0.42) PDE10AKCNJ1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL31400633 0.92 KMT2A (0.40) PDE10AMAP4K4SMN1; SMN2ALDH1A1RAB9A
SCHEMBL31400535 0.92 KMT2A (0.40) PDE10AMAP4K4SMN1; SMN2ALDH1A1RAB9A
SCHEMBL31400796 0.92 KCNJ1 (0.40) PDE10AKCNJ1SMN1; SMN2ALDH1A1RAB9A
SCHEMBL31400553 0.89 MAP4K4 (0.39) MAP4K4SMN1; SMN2ALDH1A1RAB9AMAPK1
SCHEMBL31400941 0.88 MEN1 (0.41) PDE10AMAP4K4SMN1; SMN2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP claimed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO claimed
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
Send feedback